Protagonist Therapeutics, Inc Depreciation
Protagonist Therapeutics, Inc (PTGX) reported Depreciation of $1.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-25
- Protagonist Therapeutics, Inc depreciation for the quarter ending 2022-12-31 was $254.00K, a 8.09% increase year-over-year.
- Protagonist Therapeutics, Inc depreciation for the quarter ending 2022-09-30 was $270.00K, a 26.76% increase year-over-year.
- Protagonist Therapeutics, Inc depreciation for the quarter ending 2022-06-30 was $259.00K, a 40.00% increase year-over-year.
- Protagonist Therapeutics, Inc depreciation for the quarter ending 2022-03-31 was $249.00K, a 38.33% increase year-over-year.
- Protagonist Therapeutics, Inc depreciation for fiscal 2025 was $1.23M, a 37.02% increase from fiscal 2024.
- Protagonist Therapeutics, Inc depreciation for fiscal 2024 was $894.00K, a 8.50% decline from fiscal 2023.
- Protagonist Therapeutics, Inc depreciation for fiscal 2023 was $977.00K, a 5.33% decline from fiscal 2022.
- Protagonist Therapeutics, Inc depreciation for fiscal 2022 was $1.03M, a 26.94% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.23M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $894.00K 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $977.00K 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $524.00K derived: sum of 2 quarters · filed 2025-02-21 | $783.00K derived: sum of 3 quarters · filed 2025-02-21 | $1.03M 10-K · filed 2025-02-21 |
| 2022-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $529.00K derived: sum of 2 quarters · filed 2022-11-08 | $778.00K 10-Q · filed 2022-11-08 | $1.01M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $508.00K 10-Q · filed 2022-08-04 | $743.00K derived: sum of 3 quarters · filed 2024-02-27 | $956.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $249.00K 10-Q · filed 2022-05-05 | $484.00K derived: sum of 2 quarters · filed 2024-02-27 | $697.00K derived: sum of 3 quarters · filed 2024-02-27 | $882.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $448.00K derived: sum of 2 quarters · filed 2024-02-27 | $633.00K derived: sum of 3 quarters · filed 2024-02-27 | $813.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $398.00K derived: sum of 2 quarters · filed 2022-11-08 | $578.00K 10-Q · filed 2022-11-08 | $766.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $365.00K 10-Q · filed 2022-08-04 | $553.00K derived: sum of 3 quarters · filed 2023-03-15 | |
| 2021-03-31 | $180.00K 10-Q · filed 2022-05-05 | $368.00K derived: sum of 2 quarters · filed 2023-03-15 | ||
| 2020-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $789.00K 10-K · filed 2023-03-15 | ||
| 2020-09-30 | $601.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $703.00K 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $527.00K 10-K · filed 2021-03-10 | |||
| 2017-12-31 | $406.00K 10-K · filed 2020-03-10 | |||
| 2016-12-31 | $317.00K 10-K · filed 2019-03-12 | |||
| 2015-12-31 | $247.00K 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $258.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |